This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Phase I Study of BMS-275183 (Oral Taxane) Given on a Daily Schedule in Combination With Esomeprazole (Nexium) in Patients With Advanced Cancer

This study has been terminated.
Information provided by:
Bristol-Myers Squibb Identifier:
First received: May 31, 2006
Last updated: February 27, 2010
Last verified: September 2007
The purpose of this study is to determine what effects Esomeprazole (Nexium) has on increasing or decreasing the amount of oral taxane in the blood, and to determine the safety of oral taxane and effect of oral taxane on the cancer.

Condition Intervention Phase
Cancer Drug: Oral Taxane Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effect of Esomeprazole on the Pharmacokinetics of BMS-275183 in Patients With Advanced Malignancies

Resource links provided by NLM:

Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • To assess the safety of taking Nexium in combination with oral taxane and the effect this combination has on oral taxane's exposure levels in the body.

Secondary Outcome Measures:
  • To assess the safety of a single dose of oral taxane followed by a therapeutic regimen of oral taxane administered twice weekly

Estimated Enrollment: 36
Study Start Date: December 2006
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Advanced cancers excluding cancers within the blood
  • Adequate kidney and liver function
  • > = 4 weeks from last course of chemotherapy

Exclusion Criteria:

  • Inability to swallow capsules
  • Other active medical disorder
  • Abnormal heart function or use of drugs that affect the heart
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00332748

United States, Delaware
Local Institution
Newark, Delaware, United States
United States, Kentucky
Local Institution
Louisville, Kentucky, United States
United States, Nevada
Local Institution
Las Vegas, Nevada, United States
Local Institution
Amsterdam, Netherlands
Sponsors and Collaborators
Bristol-Myers Squibb
  More Information

Additional Information: Identifier: NCT00332748     History of Changes
Other Study ID Numbers: CA165-030
Study First Received: May 31, 2006
Last Updated: February 27, 2010

Additional relevant MeSH terms:
Antineoplastic Agents
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on June 23, 2017